Updates in the Treatment of Pediatric Pulmonary Arterial Hypertension

Area of Science:

• Pediatric Cardiology
• Pulmonary Hypertension Research
• Pharmacotherapy Development

Background:

• Pediatric pulmonary arterial hypertension (PAH) is a severe condition characterized by high pulmonary vascular resistance and pressure.
• Current US pediatric PAH treatment guidelines are largely extrapolated from adult data, lacking pediatric-specific evidence.
• Existing treatments include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin agents.

Purpose of the Study:

• To review current data and clinical trial progress in pediatric PAH pharmacotherapy.
• To highlight the need for developmentally informed treatment strategies in children.
• To emphasize the necessity of updated, pediatric-specific treatment guidelines.

Main Methods:

• Consolidation of contemporary data on pediatric PAH pharmacotherapy.
• Review of highlights from ongoing clinical trials in pediatric PAH.
• Analysis of current treatment algorithms and emerging therapeutic developments.

Main Results:

• Therapeutic landscape is evolving with new monotherapy and combination regimens.
• Investigational trials are exploring interventional/surgical options for improved outcomes.
• Differences exist between monotherapy and combination approaches.

Conclusions:

• A shift towards precise, developmentally informed pharmacotherapy is needed for pediatric PAH.
• Updated guidelines incorporating pediatric-specific trials are essential.
• Harmonized labeling and long-term safety surveillance are critical for pediatric PAH management.